First clinical study with a digital therapy (DTx) in patients with IPF to address the psychological symptom burden in this diseaseFirst patient enrolled in US pilot phase leading up to the US
The imaging biomarker has demonstrated superior prognostic value compared with traditional measures, and may provide a more reliable measurement of the effects of novel therapies in clinical
Treatment with Xywav resulted in clinically meaningful improvement in idiopathic hypersomnia symptoms, including excessive daytime sleepiness, sleep inertia and prolonged sleep duration with
ODE for IH for adults follows June 2021 grant of ODE for treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy DUBLIN, Jan. 3, 2022 /PRNewswire/
- Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's AI-drug discovery platform and experimentally validated by AstraZeneca - Announcement represents the